Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

Employees - 12, CEO - Francisco D. Salva, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -9.79, Piotroski Score(max is 10): 2, Working Capital: $9210360, Total Assets: $12126804, Retained Earnings: $-72448436, EBIT: -11435523, Total Liabilities: $1646521, Revenue: $0

AryaFin Target Price - $0.33 - Current Price $ - Analyst Target Price $